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Abstract
Background: In the last five years, countries have been faced with changing their malaria treatment policy to an
artemisinin-based combination therapy (ACT), many with no national data on which to base their decision. This
is particularly true for a number of West African countries, including Guinea, where these studies were
performed. Two studies were conducted in 2004/2005 in programmes supported by Medecins Sans Frontieres,
when chloroquine was still national policy, but artesunate (AS)/sulphadoxine-pyrimethamine (SP) had been used
in refugee camps for two years.
Methods: In Dabola (central Guinea), 220 children aged 6–59 months with falciparum malaria were randomized
to receive either AS/amodiaquine (AQ) or AS/SP. In vivo efficacy was assessed following the 2003 World Health
Organization guidelines. In a refugee camp in Laine (south of Guinea), where an in vivo study was not feasible due
to the unstable context, a molecular genotyping study in 160 patients assessed the prevalence of mutations in the
dihydrofolate reductase (dhfr) (codons 108, 51, 59) and dihydropteroate synthase (dhps) (codons 436, 437, 540)
genes of Plasmodium falciparum, which have been associated with resistance to pyrimethamine and sulphadoxine,
respectively.
Results: In Dabola, after 28 days of follow-up, Polymerase Chain Reaction (PCR)-adjusted failure rates were 1.0%
(95%CI 0–5.3) for AS/AQ and 1.0% (95%CI 0–5.5) for AS/SP. In the refugee camp in Laine, the molecular
genotyping study found three dhfr mutations in 85.6% (95%CI 79.2–90.7) patients and quintuple dhfr/dhps
mutations in 9.6% (95%CI 5.2–15.9).
Conclusion: Both AS/AQ and AS/SP are highly efficacious in Dabola, whereas there is molecular evidence of
established SP resistance in Laine. This supports the choice of the national programme of Guinea to adopt AS/
AQ as first line antimalarial treatment. The results highlight the difficulties faced by control programmes, which
have gone through the upheaval of implementing ACTs, but cannot predict how long their therapeutic life will be,
especially in countries which have chosen drugs also available as monotherapies.
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Background
In the last five years, countries have been faced with
changing their malaria treatment policy to an artemisinin-
based combination therapy (ACT), many with no
national data on which to base their decision. This is par-
ticularly true for a number of West African countries; the
Republic of Guinea is a good example. Indeed, when the
National Malaria Control Programme (NMCP) of Guinea
initiated its treatment policy change for treatment of non-
severe malaria, replacing chloroquine (CQ) with an ACT,
the only data available of antimalarial efficacy were results
from two 14 day studies of CQ efficacy conducted in the
South of Guinea (N'Zerekore) in 2000 and 2001, which
reported failure rates of 24% and 28%, respectively
(NMCP, 2001). Nevertheless, high resistance to sul-
phadoxine-pyrimethamine (SP) and relatively high resist-
ance to AQ were already documented in two
neighbouring countries, as high as 52% and 46% for SP
and 19% and 30% for AQ in Liberia and Sierra Leone,
respectively [1-3].
Results of studies carried out by Médecins Sans Frontières
(MSF) in two different regions of Guinea where the organ-
ization is supporting treatment of malaria are reported: an
in vivo efficacy study which assessed the efficacy of two
potential ACT candidates (AS/SP and AS/AQ) to replace
the first line CQ treatment in Dabola prefecture (central
Guinea) and the assessment of SP resistance from a geno-
typic analysis in the Lainé Liberian refugee camp (South
Guinea) where AS/SP was used since 2002 and where it
was not possible due to security reasons to conduct an in
vivo efficacy study (Figure 1). The Ministry of Health of
Guinea approved both studies. Written informed consent
was obtained from each included patient, or carer.
Methods
In vivo study
Study site
Dabola prefecture (114,000 inhabitants) has an average
altitude of 1,200 m and seasonal perennial malaria, with
increased transmission between June and October. Plas-
modium falciparum is the predominant species. Dabola
reported 15,221 clinical malaria cases in 2003, accounting
for 30% of the total outpatient consultations (MOH,
2003).
Inclusion procedure
The efficacy study was based on the last WHO recommen-
dations for the assessment and monitoring of antimalarial
drug efficacy for area of high transmission [4]. Children
aged 6 to 59 months with measured fever (axillary tem-
perature ≥ 37.5°C) were screened from outpatient lines.
Map of Republic of Guinea and study sites Figure 1
Map of Republic of Guinea and study sites.
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Children with a P. falciparum mono-infection and asexual
parasitaemia between 2,000 and 200,000/µL were eligible
for inclusion to the study. Exclusion criteria were (i) signs
of severity or severe malaria according to WHO criteria,
which included severe anaemia defined by haemoglobin
< 5 g/dl [5], (ii) history of allergic reactions to the study
drugs, (iii) presence of a concomitant febrile condition
with the potential to confound study outcome (e.g. ARI,
measles, severe diarrhoea, etc.) and (iv) severe malnutri-
tion [4].
Treatment and follow-up
Study regimens consisted of either sulphadoxine-
pyrimethamine 1.25-mg/Kg stat (Fansidar®, Roche,
France); or amodiaquine 30 mg/Kg base divided into
three daily doses of 10 mg/Kg (Camoquin®, Parke-Davis,
Senegal); each combined with artesunate at a daily dose of
4 mg/Kg on days 0, 1 and 2 (Arsumax®, Guilin Pharma-
ceutical Works, China). Drugs were crushed and mixed
with water and sugar, given in a spoon or a syringe to
small children. All doses were directly observed and
repeated if vomiting occurred within 30 minutes. Patients
were randomly allocated (blocks of 20), without conceal-
ment, to receive either AS/SP or AS/AQ.
On day 0, blood samples were taken for haemoglobin
measurement, parasitaemia including gametocytaemia
and possible genotypic analysis to distinguish recrudes-
cence from re-infection in the event of parasite recurrence.
After treatment (days 0, 1, and 2), children were re-
assessed clinically and parasitologically on days 3, 7, 14,
21, and 28. Children, who were parasitaemic but asymp-
tomatic during follow-up were asked to return to the clinic
every three days. Gametocyte carriage was re-measured at
day 28, and a second blood sample for PCR genotyping
was collected in case of symptomatic recurrent parasitae-
mia occurring after day 9 (recurrences on or before day 9
were assumed to be recrudescence, i.e. true failures), or at
the end of follow-up in the presence of parasitaemia with-
out symptoms (MSF/Epicentre guidelines). Rescue ther-
apy (quinine hydrochloride 10 mg/Kg/8 hourly for seven
days) was administered to treatment failures, orally or
parenterally according to the patient's clinical condition.
Children were withdrawn from the study in case of (i)
vomiting any study dose twice, (ii) withdrawal of consent,
(iii) onset of a serious febrile illness, (iv) intake of any
drug with antimalarial properties, (v) missing any treat-
ment dose, (vi) mixed species parasitaemia or (vii) any
protocol violation. Patients who missed follow up visits
and did not come on the successive day despite tracing
were considered lost to follow up. Patients were classified
as early treatment failure (ETF), late clinical failure (LCF),
late parasitological failure (LPF) or adequate clinical and
parasitological response (ACPR) as per WHO definitions
[4].
Laboratory methods
Capillary blood was obtained by fingerprick. Thick and
thin films, prepared on the same slide, were stained with
10% Giemsa (pH 7.2) for 15 minutes. Asexual parasitae-
mia was quantified against 200 to 500 leukocytes, assum-
ing a white blood cell count of 8000/µL [6]. Presence of
gametocytes was recorded through this same method. All
slides were re-read and any discordance (positivity, spe-
cies or density for parasitaemia below 2,000 or above
2,000,000/µL) was resolved by a third reader. External
quality control on a random sample of 92 slides was car-
ried out by an independent and experienced laboratory
technician in Geneva and showed only two negative/pos-
itive discordances (2.2%), which did not change the out-
come classification. Haemoglobin was measured using
the Lovibond technique (Assistant Co., Sondheim Rhon,
Germany). Anaemia was defined as haemoglobin (Hb) <
11 g/dl [7].
Blood samples for PCR analysis were collected on Isoc-
ode® kits (Schleicher & Schuell, Ecquevilly, France). Kits
were air dried and stored in cool and dark boxes with des-
iccants. Genotypic analysis was performed at the Epicen-
tre laboratory at Mbarara University (Uganda) according
to a published method considering the three P. falciparum
gene loci merozoite surface protein-1 (msp-1), merozoite
surface protein-2 (msp-2), and glutamate rich protein
(GLURP) [8]. Cases in which pre- and post-treatment gen-
otypes were identical were considered as recrudescence,
i.e. failures; cases in which pre- and post-treatment geno-
types were different were considered as re-infections;
mixed genotypes were classified as failures.
Sample size
As no reliable estimates of antimalarial efficacy were avail-
able, all our calculations were based on an estimated 50%
failure rate and a desired precision of 10%. Allowing for a
type-1 error of 0.05 and considering a 15% drop out rate,
110 patients per study group were needed.
Data entry and analysis
Records were entered in Epidata 3.0 (The Epidata associa-
tion, Odense Denmark) and analysed on SPSS® 11.0 for
Windows (SPSS Inc. Chicago, Illinois) and EpiInfo 6.04b
(CDC, Atlanta; 1996). Data entry errors were checked
individually on each record. Appropriate statistical tests
(Chi2, ANOVA, Kruskal-Wallis were used to compare the
two groups. The main outcome was day-28 failure rate,
defined as the number of true failures (recurrences on or
before day 9 + PCR-confirmed recrudescence occurring
after day 9) over the total number of patients analysed.
Losses to follow-up and withdrawn patients, as well asMalaria Journal 2007, 6:54 http://www.malariajournal.com/content/6/1/54
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PCR-confirmed new infections and indeterminate PCR
results were excluded from the analysis according to the
last WHO guideline for assessment and monitoring of
antimalarial efficacy [4].
Genotypic analysis
Lainé refugee camp (22,000 Liberian refugees and average
altitude 470 m) borders Ivory Cost and Liberia. Malaria
transmission is perennial. A total of 10,541 malaria con-
firmed cases were recorded in 2004 (Figure 1).
Patients from the outpatient clinic of the Lainé refugee
camp with measured fever (axillary temperature ≥
37.5°C) were screened for falciparum malaria using the
Paracheck-Pf® rapid diagnostic test. After microscopic con-
firmation, samples from 181 consecutive patients were
collected on Isocode® kits and transported to the London
School of Hygiene and Tropical Medicine (LSHTM, Lon-
don, United Kingdom). After DNA extraction, the PCR-
Sequence Specific Oligonucleotide Probing (PCR-SSOP)
method was used for molecular genotyping of point
mutations in the dihydrofolate reductase (dhfr) and dyhy-
dropteroate synthetase (dhps) genes [9,10]. This method
involves the PCR amplification of coding regions of dhfr
and  dhps  genes, which are fixed onto membranes and
probed with SSOP designed to detect each of the single
base-pair changes which code for substitutions at codons
51 (N to I), 59 (C to R), and 108 (S to N, or T) of dhfr and
codons 436 (S to A, or F), 437 (A to G), and 540 (K to E)
of dhps. Since point mutations occur in a number of differ-
ent configurations, each conferring differing degrees of
resistance, data were to summarized in two ways. Firstly,
by showing the allelic haplotypes (combination of muta-
tions which are in the same gene), which were found
among the parasites in Lainé. These can be determined
easily in infections where there is a single genotype
because the blood stage form of the parasite is haploid but
are difficult or impossible to resolve in mixed infections
[9,10]. The frequency of allelic haplotypes in the parasite
population was calculated after excluding mixed infec-
tions. The second way in which were summariszd the
data, was to calculate the proportion of all infections
(mixed and non-mixed), which were found to contain all
three dhfr mutations plus the dhps 437 and 540 mutations.
This particular genotype has been shown to be associated
with SP treatment failure in a number of East African
countries: Kenya, Malawi and Uganda but has only been
reported rarely in West Africa [11-13].
Results
Efficacy study
Between June and September 2004, 513 children were
screened, of whom 376 (73.9%) had a P. falciparum
mono-infection and 220 (42.2%) were included (Figure
2). Of the 220 patients included, 2 (0.9%) were lost to fol-
low-up (AS/AQ group) and 5 (2.3%) withdrawn (1 in the
AS/AQ group, 4 in the AS/SP group). Baseline characteris-
tics were similar across treatment groups (Table 1). After
28 days of follow-up, there were 6/107 (5.6%) recurrent
parasitaemia in the AS/AQ group and 9/106 (8.5%) in the
AS/SP group (p = 0.41). Among these 15 recurrences, one
was an ETF (true failure, AS/SP) and 14 were late failures
that occurred after day 9. Out of these 14 samples that
underwent PCR genotyping, 13 had a result available: 12
were re-infections excluded from the analysis (five AS/AQ,
seven AS/SP) and one was a recrudescence (true failure,
AS/AQ). The 28-day PCR-adjusted failure rate was, there-
fore, 1/102 (1.0%, 95%CI 0–5.3) in the AS/AQ group and
1/99 (1.0%, 95%CI 0–5.5) in the AS/SP group (Table 2).
After the end of treatment (day 3), 95.4% (105/110, AS/
AQ) and 96.3% (103/107, AS/SP) of the patients had
cleared their parasitaemia (p = 0.15). Compared to base-
line, gametocyte carriage was significantly decreased after
28 days of follow-up in both groups (from 11.8% (13/
110) to 3.8% (4/106) in the AS/AQ group; from 10.0%
(11/110) to 2.0% (2/101) in the AS/SP group; p = 0.03
and p = 0.01 for each comparison, respectively).
Genotypic analysis
Among the 181 samples sent for analysis, there was no
amplification of the coding regions of dhfr in 21 cases
(11.6%) or of dhps in 45 cases (24.9%). One analysis was
Table 1: Baseline characteristics of included patients in the in vivo study, Dabola
Characteristics AS/AQ (n = 110) AS/SP (n = 110) p
Gender ratio M/F 54/56
0.96
51/59
0.86
0.16
Age (months) Mean (SD) 29.5 (14.9) 28.7 (12.9) 0.68
Middle-upper arm circumference (mm) Mean (SD) 149.2 (12.5) 147.6 (10.8) 0.29
Axillary temperature (°C) Median (IQR) 39.0 (37.8–39.8) 39.1 (38.1–40.0) 0.46
Haemoglobin (g/dL) Mean (SD) 8.7 (2.0) 8.7 (1.9) 0.92
Asexual parasitaemia (/µL) Geometric mean (IQR) 40,492
20,121–97,615
34,716
15,658–41,226
0.45
Gametocyte carriage n (%)
95% CI
13 (11.8)
6.4 – 19.3
11 (10.0)
5.1 – 17.8
0.66
SD: Standard deviation IQR: Inter-Quartile RangeMalaria Journal 2007, 6:54 http://www.malariajournal.com/content/6/1/54
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incomplete for the coding regions of dhps. Results were
reported for 160 samples for dhfr mutations at all of three
codons 108, 51 and 59, 135 samples for dhps mutations at
codons 436, 437 and 540 and for 135 samples for com-
bined dhfr-dhps mutations (Tables 3 and 4). Table 3 shows
the frequency of allelic haplotypes among the parasite
population and this is based upon a subset of infections
which were either single or majority genotype infections
dhps n = 114, dhfr n = 148 and dhfr-dhps combined n =
110. The proportion of infections which contained all
three dhfr mutations whether mixed or not, was 85.6%
(137/160, 95%CI 79.2–90.7); the proportion containing
double mutant dhps  (437, 540) was 10.4% (14/135,
95%CI 5.8–16.8); and the proportion containing all five
was 9.6% (13/135, 95%CI 5.2–15.9) (Table 4).
Discussion
The in vivo study in Dabola provides important data on
the efficacy of SP and AQ when used in combination with
an artemisinin derivative in a country where very limited
information on antimalarial drug efficacy was available.
The NMCP of Guinea recently decided to adopt AS/AQ as
first line antimalarial treatment for uncomplicated
malaria to replace CQ (Roll Back Malaria 2006). In
Dabola prefecture, based on the very good efficacy
described here (above 95%) both AS/SP or AS/AQ are very
good alternatives to CQ. Although important, these
results provide information applicable only to the local
area where the studies were conducted, and caution
should be taken before extrapolating the results to the
whole country. Site-specific patterns of health service uti-
lization or malaria transmission intensity may result geo-
graphic differences in the efficacy of a drug [14].
The results of the genotypic study in Lainé are also impor-
tant because they document the level of resistance to SP in
a setting where day-28 in vivo efficacy study was not feasi-
ble due to the unstable context related to security factors
and where the combination AS/SP was already used since
two years as first line treatment. Although, the genotypic
findings cannot be correlated with any in vivo data from
the area and that their predictive value for estimating how
long the efficacy of SP used in combination with AS can
be sustained is unknown, it was important to be able to
document the presence and frequency of molecular mark-
ers of SP resistance in this setting. The frequency of the
quintuple mutant dhfr-dhps genotype was quite high 7.3%
(and its prevalence among patients was 9.6%). In Africa,
the dhfr triple mutant genotype (108, 51 and 59), which
is a resistance marker of pyrimethamine has been shown
to be strongly associated with resistance to SP, and this
association is strengthened when the triple mutation is
associated to the double dhps  mutant (437, 540), the
quintuple mutation being the most predictive marker of
treatment failure [12]. These results in Lainé are consistent
with the high failure rate of SP from in vivo studies in
neighbouring Liberia and Sierra Leone [1,2]. The results of
Lainé are likely to be specific to that area, since the study
population was composed of Liberian refugees living in
different conditions from the native population in the sur-
rounding area and with access to AS/SP, whereas in other
areas of the country patients were treated with CQ. There-
fore, these results were of limited relevance in guiding the
national programme in their choice of ACT.
In countries with no or very limited efficacy data of mon-
otherapies (SP and AQ) or ACTs, such as in Guinea,
choosing a standard ACT suitable for the whole country is
difficult. The choice is usually based on a pragmatic deci-
sion, taking into consideration the potential risk of low
efficacy based on data from neighbouring countries, such
as Liberia and Sierra Leone in the Guinea case, availability
and affordability of the ACT, which is still a limitation for
artemether-lumefantrine and other advantages and disad-
vantages of the remaining ACT candidates such as dosing
regimen and tolerance. The advantages of AS/SP and AS/
AQ have been well described [15,16]. Their price, when
available in blister, is similar, about 1.5 US$ each. AS/SP
has the advantage that SP is administrated as a single dose
and can be delivered to pregnant women during 2nd and
3rd trimesters. Therefore, considering the high levels of
resistance to SP in neighbouring countries [1-3], the rather
short useful therapeutic lifespan of SP-containing combi-
nations [14] and the fixed combination of AQ/AS just reg-
Table 2: Therapeutic response at day 28, after PCR adjustment, in vivo study, Dabola
Results AS/AQ (n = 102) AS/SP (n = 99)
N % 95%CI N % 95%CI
Early Treatment failure 00 0 – 3 . 5 1 1 0 – 5 . 5
Late Treatment Failure 1 1.0 0–3.5 0 0 0–3.7
Total failure 1 1.0 0–5.3 1 1.0 0–5.5
ACPR 101 99.0 94.7–99.8 98 99.0 94.5–99.8
Outcome classification according to WHO guidelines [4]
Late Treatment Failure = Late Clinical Failure + Late Parasitological Failure
ACPR: Adequate Clinical and Parasitological Response
Outcome classification is WHO (2003)Malaria Journal 2007, 6:54 http://www.malariajournal.com/content/6/1/54
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Details on study inclusions and follow-up Figure 2
Details on study inclusions and follow-up.
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istered in Morocco, AS/AQ seems to have been a good
choice. These advantages may explain why other African
countries such as Burundi, Cameroon, Côte d'Ivoire,
DRC, Equatorial Guinea, Gabon, Ghana, Liberia, Mada-
gascar, Senegal, Sierra Leone and Sudan have already
adopted AS/AQ as first-line therapy (Roll Back Malaria
2006).
Concurrent in vivo and molecular studies of AS-SP are
needed to see if there is a correlation between molecular
findings and in vivo response. Genotypic studies are much
simpler to perform than in vivo studies, particularly in
countries in unstable situations. The predictive value of
molecular results for estimating how long the useful ther-
apeutic life of SP used in combination with artesunate
should be further investigated.
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Table 4: Frequency of individuals with molecular makers associated to SP resistance, Lainé refugee camp
Prevalence No of individuals 
(Single+majority+mixed aplotypes)
%9 5 %  C I
dhps (N = 135)
Double mutant 437&540 14 (6+2+6) 10.4 5.8–16.8
Double mutant 436&437 36 (22+7+7) 26.7 19.4–35.0
dhfr (N = 160)
triple mutant 51–59–108 137 (121+5+11) 85.6 79.2–90.7
dhfr and dhps (N = 135)
triple mutant 51–59–108 with double mutant 437&540 13 (6+2+5) 9.6 5.2–15.9
Single aplotype: only one single nucleotide polymorphism (SNP) was present
Majority aplotype: volume minority SNP value was more than half of the volume of the majority SNP
Mixed aplotype: volume minority SNP value was less than half of the volume of the majority SNP [9]
Table 3: Frequency of dhfr and dhps mutant alleles, genotypic study, Lainé refugee camp
Genotype Frequencies n% 9 5 %  C I
dhps (N = 114)
wild type, 8 7.0 3.1–13.6
single mutant 436 31 27.2 19.3–36.3
single mutant 437 38 33.3 24.8–42.8
double mutant 436–437 29 25.4 17.7–34.4
double mutant 437–540 8 7.0 3.1–13.6
dhfr (N = 148)
wildtype 20 13.5 8.4–20.1
double mutant 59–108 2 1.4 0.2–4.8
triple mutant 51–59–108 126 85.1 78.4–90.4
dhps and dhfr combined (N = 110)
quintuple mutant: dhfr 51–59–108 &dhps 437–540 8 7.3 3.2–13.8
quintuple mutant: dhfr 51–59–108 & dhps 436–437 27 24.5 16.8–33.7
dhfr 51–59–108 & dhps single mutant 54 49.1 39.4–58.8
Three or less mutations 21 19.1 12.2–27.7
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